• Micro Imaging Technology agreed to acquire Cellmyx, adding an adipose tissue grafting and regenerative medicine tools business to its aesthetics portfolio.
• Cellmyx markets the intelliFat BOD system, cleared under FDA 510(k) in early 2023 for use in orthopedic, plastic, and cosmetic procedures.
• The deal follows Micro Imaging Technology’s SaltMed/SaltFacial acquisition, which closed in late December 2025, positioning the group for broader manufacturing expansion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Micro Imaging Technology Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606050845PR_NEWS_USPR_____LA76681) on June 05, 2026, and is solely responsible for the information contained therein.